top of page

Reaching beyond all other ablative therapies

The 1st and only translumenal delivery of ultracold cryoablation.

Phase Therapeutics custom x-ray or MRI graphic of target therapy site, the upper body.

APPLICATIONS

The 1st and only translumenal delivery of ultracold cryoablation designed to evolve ablation from a secondary procedure to a primary modality.

01

Lung

  • For the 1st time, cryoablation delivery through a bronchoscope

  • Same platform can be leveraged for cryobiopsy

02

Pancreatic

  • Same translumenal platform as lung

  • For the 1st time, cryoablation delivered via endoscopic ultrasound

  • Benefits vs heat with greater precision and real-time visualization

03

Percutaneous

  • Cryogenerator applicable to all percutaneous ablation

  • Colder, faster, and more precise than any other cryoablation

  • Indication & market runway:  Breast, Liver, Kidney, Prostate

INNOVATION

How are we going to stop tumor progression in a single outpatient procedure?

  • Novel:  Mixed-phase cryogen, fastest & coldest cryoablation
    ​​​​

  • Translumenal:  The ONLY flexible endoscopic cryoablation option

​

  • Familiar:  Same procedure & methods as diagnostic approaches

​

  • Precise:  Only real-time ablation visualization

​

  • Safe:  Minimizes collateral damage and side effects

​

  • Immunogenic:  Generates antigens, provokes immune response

​

  • Synergistic:  Combine with chemo, immunotherapy & radiation 

​

*Does not preclude pre/post-treatment with other standard care modalities.

Nurse embracing a post-op patient in wheelchair recovery.
MISSION

We believe there's a better way

Phase Therapeutics is a medtech startup focused on the commercialization of a novel ultracold cryoablation designed to stop tumor progression for inoperable cancer patients in a single procedure. 

Get
in Touch

bottom of page